Story perspectives

AI Trial Shows Rentosertib Cuts Predicted Biological Age in IPF

9/8/2026

Summary

Story summary

Insilico Medicine reports its AI-generated drug rentosertib lowered predicted biological age in a trial.
The double-blind study enrolled 42 idiopathic pulmonary fibrosis patients and compared rentosertib with placebo.
Six independently developed proteomic aging clocks all showed significant age reduction for rentosertib recipients.
Placebo-treated participants showed no age reduction, with some clocks indicating age increase.
Scientists caution that aging-clock metrics lack universal acceptance and further trials are required before approval.

1 of 1

Story summary

Insilico Medicine reports its AI-generated drug rentosertib lowered predicted biological age in a trial.
The double-blind study enrolled 42 idiopathic pulmonary fibrosis patients and compared rentosertib with placebo.
Six independently developed proteomic aging clocks all showed significant age reduction for rentosertib recipients.
Placebo-treated participants showed no age reduction, with some clocks indicating age increase.
Scientists caution that aging-clock metrics lack universal acceptance and further trials are required before approval.